Table S4. Characteristics of patients receiving ICIs.
| Characteristics | n (%) |
| ICI, immune checkpoint inhibitor; CLDN18.2, claudin 18 isoform 2; dMMR, mismatch repair-deficient; pMMR, mismatch repair-proficient; NA, not available; EBV, Epstein-Barr virus; HER2, human epidermal growth factor receptor 2; TMB, tumor mutational burden; CPS, combined positive score; PD-L1, programmed death-ligand 1. | |
| CLDN18.2 status | |
| CLDN18.2 ≥2+, 40% | 52 (62.7) |
| CLDN18.2 <2+, 40% | 31 (37.3) |
| CLDN18.2 ≥2+, 70% | 42 (50.6) |
| CLDN18.2 <2+, 70% | 41 (49.4) |
| MMR status | |
| dMMR | 1 (1.2) |
| pMMR | 77 (92.8) |
| NA | 5 (6.0) |
| EBV status | |
| Positive | 3 (3.6) |
| Negative | 66 (79.5) |
| NA | 14 (16.9) |
| HER2 status | |
| Positive | 12 (14.5) |
| Negative | 70 (84.5) |
| NA | 1 (1.2) |
| TMB status | |
| TMB≥10 | 4 (4.8) |
| TMB<10 | 13 (15.7) |
| NA | 66 (79.5) |
| CPS status | |
| PD-L1 CPS≥1 | 44 (53.0) |
| PD-L1 CPS<1 | 35 (42.2) |
| NA | 4 (4.8) |
| PD-L1 CPS≥5 | 34 (41.0) |
| PD-L1 CPS<5 | 45 (54.2) |
| NA | 4 (4.8) |
| PD-L1 CPS≥10 | 26 (31.3) |
| PD-L1 CPS<10 | 53 (63.9) |
| NA | 4 (4.8) |